Ezetimibe final guidance [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2019-09-28 12:11 (842 d 14:23 ago) – Posting: # 20650
Views: 3,460

Hi Mutasim & all,

yesterday at BioBridges Paola Coppola (MHRA, PKWP observer) presented the state of affairs. The ezetimibe guidance is finalized and will be published soon. No changes to the draft. You are right and I was wrong. One should indeed measure both ezetimibe and its glucuronide. BE should be based on their sum* only.

I still think that’s stupid. Both methods have errors (inaccurate, imprecise). If you evaluate the sum of concentrations, errors will sum up as well. Given, the concentrations of the glucuronide are two orders of magnitude higher than the parent’s and hence, the impact of the latter is negligible.
At the BioInternational 1994 in Munich there was a nice distinction between “Need to know” and “Nice to know”. I don’t like the idea that something which is only nice to know (i.e., not used in the assessment for BE) is mandatory in a guidance. :thumb down:



Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,829 posts in 4,566 threads, 1,555 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Tuesday 01:34 CET (Europe/Vienna)

The generation of random numbers is too important
to be left to chance.    Robert R. Coveyou

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5